BridgeBio Pharma (BBIO) PT Raised to $91 at Goldman Sachs, Following Clinical Update
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $79.83 -1.7%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs analyst Paul Choi raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $91.00 (from $83.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BridgeBio Pharma (BBIO) PT Raised to $106 at Canaccord
- Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities
- BridgeBio Pharma (BBIO) PT Raised to $107 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
